FDA Calls Novartis' Melanoma Combo Drug a Breakthrough Post author:Sam Post published:October 22, 2017 Post category:BioPharma The FDA based its decision on data from the COMBI-AD Phase III trial. Source: BioSpace You Might Also Like Flexion Eyes Creation of 100 New Sales Jobs to Sell Just-Approved Osteoarthritis Drug October 10, 2017 <b>Luye Life Sciences</b> Expands Global Reach As New Boston R&D Center Opens July 16, 2017 More R&D Fat is Trimmed as Biogen Closes Doors on UK's Convergence Pharma May 11, 2017
Flexion Eyes Creation of 100 New Sales Jobs to Sell Just-Approved Osteoarthritis Drug October 10, 2017
